Compare US Global Jets ETF (JETS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Viatris Inc — how do they compare? US Global Jets ETF trades at $31.7, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals.
| JETS | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $17.86 |
52-Week Low | $23.64 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.81B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $32.54, down 0.31% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights mixed sentiment, including JetBlue's earnings beat lifting airline stocks but fuel cost pressures and geopolitical risks weighing on the sector. The ETF faces volatility from oil price swings and competitive ETF comparisons.
Outlook is cautious due to high sensitivity to fuel costs and travel demand cycles. Opportunities exist if oil remains low, but risks from Middle East tensions and economic slowdowns could pressure earnings. Investors should weigh JETS' cyclical nature against broader aerospace ETFs for diversification.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
